Pilot Investigation on the Health Benefits of Sub Acute (12 Week) Whole-body Vibration Training
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Whole-body Vibration
- Sponsor
- Augusta University
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Change in VO2 Peak
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The overall goals of this pilot investigation are to determine 1) the feasibility of conducting home based WBV studies, and 2) to determine if sub-acute home based WBV can improve a) exercise capacity, b) conduit- and micro- vascular function, and c) skeletal muscle function.
Detailed Description
Cardiovascular disease (CVD) is the leading cause of death in the world and many comorbid conditions (i.e. diabetes, obesity) can affect overall CVD risk. There is increasing interest into the role that skeletal muscle health plays in mediating CVD risk, particularly in metabolic disease states (ie. obesity and diabetes). Whole body vibration (WBV) has emerged as an exercise mimetic that may be more tolerable than traditional modes of exercise, such as treadmill walking/running or cycling. Similar to traditional exercise modalities, WBV can elicit beneficial metabolic effects. In fact, a single bout of WBV increases circulating concentrations of IL-6, which correspond with the normalization of glucose and insulin in obese individuals. The proposed pilot investigation will provide the foundation to begin understanding the molecular and physiological mechanisms of how sub-acute WBV can improve overall CVD risk. We hypothesize that home based WBV will decrease CVD risk by improving skeletal muscle and vascular function via a decrease in systemic inflammation.
Investigators
Ryan Harris
Professor
Augusta University
Eligibility Criteria
Inclusion Criteria
- •Men and women (\> 18 yrs old)
- •All races
Exclusion Criteria
- •\<18 years old
- •Clinical diagnosis of hepatic, cardiovascular, or renal disease
- •Diabetic complications (i.e. macrovascular, microvascular, or autonomic)
- •Pregnancy
- •Direct vasoactive medications (i.e. nitrates)
Outcomes
Primary Outcomes
Change in VO2 Peak
Time Frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline relative (mL/kg/min) peak oxygen consumption (VO2) during maximal exercise test at 12 weeks
Change in Flow-Mediated Dilation (FMD)
Time Frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline brachial artery flow mediated dilation at 12 weeks.
Change in Skeletal Muscle Mitochondrial Function
Time Frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline skeletal muscle mitochondrial function at 12 weeks. Measured using Near Infrared Spectroscopy (NIRS). Values are an index of phosphocreatine recovery expressed as a rate constant (min-1)
Change in Pulse Wave Velocity (PWV)
Time Frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change from baseline PWV at 12 weeks. Measured by Shygmocor Xcel in m/s.
Change in Post Occlusive Reactive Hyperemia (PORH)
Time Frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
Change from baseline PORH at 12 weeks. Measured by Laser Speckle Contrast Imager (Moor FLPI).
Change in IL-6
Time Frame: pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
change from baseline concentrations of Interleukin 6 (IL-6) obtained via blood draw at 12 weeks.